文献速递神经肿瘤

复发高级别胶质瘤中CDK4/6与mTOR抑制的0/1期试验:单核转录组学、药代与药效研究

Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma.
PubMed 文献 · Neuro Oncol · 2026-01-01

该0/1期临床试验纳入24例复发高级别胶质瘤患者,联合使用ribociclib(CDK4/6抑制剂)与everolimus(mTOR抑制剂),评估脑内药物浓度、靶点调控及恶性细胞状态变化。结果显示ribociclib在非强化肿瘤区浓度超过CDK4/6抑制的生化IC50,而everolimus未检出,ribociclib治疗与增殖细胞减少及恶性细胞状态偏移相关。

要点

  • ribociclib在400和600 mg QD剂量下脑内非强化区未结合浓度超过CDK4/6抑制IC50
  • everolimus在所有剂量水平肿瘤区未结合浓度均低于0.1 nM未检出
  • ribociclib治疗与Ki-67阳性细胞显著减少及 cycling/神经祖样恶性细胞比例降低相关

核心结论

  • 0/1期手术试验整合药代、药效与单核转录组学可评估靶向药对恶性细胞状态的影响。
  • ribociclib可达到脑内有效浓度并调控CDK4/6相关恶性细胞状态,而everolimus脑内暴露不足。

研究设计与样本

  • 0/1期临床试验纳入24例复发高级别胶质瘤患者,肿瘤需CDKN2A/B缺失或CDK4/6扩增、PTEN缺失或PIK3CA突变且Rb野生型。
  • 联合口服ribociclib(CDK4/6抑制剂)与everolimus(mTOR抑制剂),评估肿瘤药代动力学、药效学及单核转录组学。

主要发现

  • 钆非强化肿瘤区中位未结合ribociclib浓度在400和600 mg QD剂量下显著高于CDK4/6抑制的生化IC50。
  • 所有剂量水平肿瘤区未结合everolimus浓度均未检出(<0.1 nM)。
  • ribociclib治疗与Ki-67阳性细胞显著减少相关。
  • 17例试验中IDH野生型复发与88例标准治疗复发肿瘤的单核RNA测序显示,ribociclib-everolimus治疗组 cycling及神经祖样恶性细胞群体比例显著更低。
  • CDK4/6抑制剂导向的恶性细胞状态偏移在3株患者来源细胞系中得到验证。

临床怎么用

  • 复发高级别胶质瘤中选择脑渗透性靶向药时,应优先验证肿瘤内未结合药物浓度是否达到生化IC50。
  • CDK4/6抑制剂ribociclib在特定分子特征(CDKN2A/B缺失或CDK4/6扩增、PTEN缺失或PIK3CA突变、Rb野生型)复发高级别胶质瘤中显示靶点调控与细胞状态效应。
  • mTOR抑制剂everolimus在此联合方案中脑内暴露不足,不宜作为该人群的脑渗透性组合组分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcomes for adult patients with high-grade glioma (HGG) remain poor, necessitating new treatment strategies. Key challenges include poor drug penetration in the brain and malignant cell state plasticity. Phase 0 studies identify agents that achieve target modulation through pharmacologically relevant brain concentrations. METHODS: A Phase 0/1 clinical trial combined the 2 targeted inhibitors ribociclib (CDK4/6 inhibitor) and everolimus (mTOR inhibitor) in recurrent HGG patients, aiming to identify brain-penetrant combinations and assess their impact on malignant cell states. We enrolled 24 patients with recurrent HGG, characterized by CDKN2A/B deletion or CDK4/6 amplification, PTEN loss or PIK3CA mutations, and wildtype retinoblastoma protein (Rb). Tumors were evaluated for pharmacokinetics, pharmacodynamics, and single nucleus transcriptomics. RESULTS: Median unbound ribociclib concentrations in gadolinium non-enhancing tumor regions were significantly above the biochemical IC50 for CDK4/6 inhibition at 400 and 600 mg QD doses. Unbound everolimus concentrations were undetectable (<0.1 nM) in tumor regions across all dose levels. Ribociclib treatment was associated with significantly decreased Ki-67-positive cells. Single-nucleus RNA sequencing of 17 on-trial IDH-wildtype recurrences and 88 standard-of-care-treated recurrences showed a significantly lower fraction of cycling and neural progenitor-like malignant cell populations in ribociclib-everolimus-treated tumors. CDK4/6 inhibitor-directed malignant cell state shifts were validated using 3 patient-derived cell lines. CONCLUSIONS: This trial underscores the value of integrating pharmacokinetics, pharmacodynamics, and single-nucleus transcriptomics in Phase 0/1 surgical studies to assess treatment effects, including malignant cell state shifts. Clini-calTrials.gov identifier: NCT03834740.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Johnson KC, Tien AC, Jiang J, et al. Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma. Neuro Oncol. 2026. PMID: 41206763. doi:10.1093/neuonc/noaf257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。